Repositioning canakinumab for non|small cell lung cancer ...

Repositioning canakinumab for non-small cell lung cancer-important ...

Canakinumab is an anti-interleukin-1β monoclonal antibody approved for use in a range of immune-related disorders.

(PDF) Repositioning canakinumab for non-small cell lung cancer ...

PDF | Canakinumab is an anti-interleukin-1β monoclonal antibody approved for use in a range of immune-related disorders.

AACR: Novartis aims to keep canakinumab's early lung cancer ...

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs ...

Synergistic effect of canakinumab with epidermal growth factor ...

The Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer-A (CANOPY-A), a phase III, randomized, ...

Synergistic effect of canakinumab with epidermal growth factor ...

The Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer-A (CANOPY-A), a phase III, randomized, double-blind, ...

Targeting Inflammation in Non-Small Cell Lung Cancer through ...

There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer · ClinicalTrials.

or third-line (2/3L) treatment of advanced non-small cell lung cancer ...

... A clinical study in atherosclerosis patients indicated that the anti-IL-1β antibody canakinumab could reduce lung cancer incidence and mortality [8].

Canakinumab adjuvant therapy for treating completelyresected non ...

Canakinumab is in clinical development as an adjuvant therapy for stage II-III non-small cell lung cancer (NSCLC) that has been surgically completely ...

Novartis provides update on Phase III study evaluating ...

Canakinumab is a first-in-class interleukin-1beta (IL-1β) inhibitor of PTI in non-small cell lung cancer10. About the CANOPY program. Novartis ...

Regulation of PD-L1 expression in non–small cell lung cancer by ...

Blockade of IL-1β activity by administration of canakinumab might thus be expected to antagonize the upregulation of PD-L1 on tumor cells.

Document is current - Crossmark - Crossref

Document is current. Any future updates will be listed below. Repositioning canakinumab for non-small cell lung cancer—important lessons for ...

Immunotherapy-based combinations in metastatic NSCLC

... tumor cells inhibits T-cell responses and ... Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology.

Lung cancer articles within British Journal of Cancer - Nature

Perspective 23 June 2022 | Open Access. Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology. Mark P ...

Mechanisms of resistance to targeted therapy and immunotherapy in ...

... cancer cells to elude immune detection ... Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology.

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind ...

GED-0408 - Drug Targets, Indications, Patents - Patsnap Synapse

01 Sep 2022·British journal of cancer. Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology. Review.

Non-small-cell lung cancer | British Journal of Cancer - Nature

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology. Mark P. Lythgoe; & Vinay Prasad. Article 31 May ...

NHS article or chapter request

Article title: Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. DOI: ISSN: Publication date: 2022 ...

Facts and Hopes on Neutralization of Protumor Inflammatory ...

53. Lythgoe. MP. ,. Prasad. V . Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology . Br J Cancer. 2022.